SYRS News and Press, Syros Pharmaceuticals Inc. From 11/14/22

Syros Pharmaceuticals, Inc. (SYRS) Q3 2022 Earnings Conference Call November 14, 2022 08:30 AM ET Company Participants Karen Hunady - Director-Corporate Communications & Investor Relations Nancy Simonian - President & Chief Executive Officer David Roth - ...

Syros Pharmaceuticals press release ( NASDAQ: SYRS ): Q3 GAAP EPS of -$3.21 beats by $0.30 . Revenue of $3.9M (-31.6% Y/Y) misses by $1.28M . The company expects that its existing cash, cash equivalents and marketable securities of $244.5M will be sufficient to...

Closed Merger with TYME Technologies and Concurrent PIPE; Proceeds from Combined Transactions Augment Cash Balance, Ending Third Quarter with Approximately $245 Million and Extending Cash Runway into 2025 Initial Data from Safety Lead-in Portion of SELECT-AML-1 Phase 2 Trial t...

Syros Pharmaceuticals ( NASDAQ: SYRS ) is scheduled to announce Q3 earnings results on Monday, November 14th, before market open. The consensus EPS Estimate is -$3.83 and the consensus Revenue Estimate is $5.18M (-9.1% Y/Y). Over the last 2 years, SYRS has beaten EPS...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Monday, November 14, 2022 to report its third quarter 2022 financial results and pr...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 clinical trial at the 64 th American Society of H...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: g0d4ather / Shutterstock.com Investors are still interested in short squeeze stocks and we’ve got them covered with the ones to watch this week! Fintel is offering up a list of the short squeeze sto...

Summary Small-cap merger arbitrages have yielded solid risk-adjusted returns. Unlike large-cap arb plays that tend to be priced efficiently, in small-cap arbitrage, individual investors willing to dig deeper can have an edge. In this article, I present two small-cap risk arbit...

Summary Syros Pharmaceuticals has recently acquired its peer Tyme Technologies. The sole purpose of the merger was to acquire TYME's cash balance. Concurrently with the merger, the largest shareholders put in an additional $130m into the company at over 30% premium to current ...

-- Cash and cash equivalents of approximately $240 million after giving effect to close -- -- Timothy C. Tyson and Andrew Oh join Syros Board of Directors -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression...